This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Sensyne Health – Appointment of Chief Scientific Officer

Sensyne Health – Appointment of Chief Scientific Officer

22 Jul 2021

Dr. David Ruau joins Sensyne Health from Bayer Pharmaceuticals Oxford, U.K. 22 July 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the ethical AI company, today announces the appointment of Dr David Ruau to the newly created role of Chief Scientific Officer with effect from 01 September 2021. In this role, David will lead the research effort at Sensyne aimed at applying ethical AI to the improvement of patient care... Read more

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

20 Jul 2021

Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and... Read more

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer

15 Jul 2021

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer Company to be led by award winning, cell therapy expert as it aims to unlock an expansive therapeutic target space by decoding natural T-cell responses in both oncology and autoimmune diseases. Oxford, UK, 15 July 2021 – T-Cypher Bio (‘T-Cypher’, or ‘the Company’), a rapidly emerging private biotech company pioneering a novel approach to TCR... Read more

Etcembly establishes new lab & office space at TOSP

Etcembly establishes new lab & office space at TOSP

08 Jul 2021

Etcembly establishes new lab & office space at TOSP Immune-focused machine learning firm joins leading AI cohort on Park Oxford, UK, July 8 2021 – Etcembly Ltd, a machine learning biotech that is decoding immune pattern recognition of T cell receptors, has moved into more than 1,000 sq ft of new laboratory and office premises within The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The... Read more

Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research

Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research

01 Jul 2021

Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research Better understanding of disease possible with accurate full length identification of all messenger RNA in a cell Oxford, UK, July 1 2021 – Research on improved techniques for single-cell RNA sequencing by ATDBio, a leader in complex oligonucleotide synthesis, and a research team at the Botnar Research Centre, University of Oxford, has been... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More